SCHEMBL6697410

SCHEMBL6697410

Cc1ccc(-c2nc(NC(=N)N)nc3ccc(Cl)cc23)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
GAA P10253 3/20 0.48
HSP90AB1 P08238 1/20 0.45
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TP53 P04637 1/20 0.44
ADORA1 P30542 2/20 0.43
NPFFR1 Q9GZQ6 1/20 0.40
NPFFR2 Q9Y5X5 1/20 0.40
KMT2A Q03164 2/20 0.40
POLB P06746 1/20 0.40
RAD52 P43351 1/20 0.40
MEN1 O00255 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MPO P05164 1/20 0.38
MAT2A P31153 1/20 0.38
MAPK1 P28482 1/20 0.37
THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6692442 0.92 MAPT (0.49) MAPTGAAHSP90AB1ALDH1A1SMN1; SMN2
SCHEMBL6700265 0.89 MAPT (0.46) MAPTGAAHSP90AB1ALDH1A1SMN1; SMN2
SCHEMBL6695182 0.87 HSP90AB1 (0.61) MAPTGAAHSP90AB1ALDH1A1SMN1; SMN2
SCHEMBL6696127 0.87 MAPT (0.59) MAPTGAAHSP90AB1ALDH1A1SMN1; SMN2
SCHEMBL6695601 0.85 MAPT (0.52) MAPTGAAHSP90AB1ALDH1A1SMN1; SMN2
SCHEMBL6695754 0.83 MAPT (0.69) MAPTGAAALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL6701110 0.82 MAPT (0.54) MAPTGAAHSP90AB1ALDH1A1SMN1; SMN2
SCHEMBL6701160 0.82 MAPT (0.54) MAPTGAAHSP90AB1ALDH1A1SMN1; SMN2
SCHEMBL6700375 0.82 MAPT (0.51) MAPTGAAHSP90AB1ALDH1A1SMN1; SMN2
SCHEMBL6690817 0.81 MAPT (0.55) MAPTGAAALDH1A1SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224965-A1 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors MERCK PATENT GMBH (DE) 2004-11-11 US claimed
EP-1274691-A1 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS MERCK PATENT GmbH (DE) 2003-01-15 EP claimed
WO-2001079186-A1 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS MERCK PATENT GMBH (DE) 2001-10-25 WO claimed
US-20040224965-A1 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors MERCK PATENT GMBH (DE) 2004-11-11 US disclosed
EP-1274691-A1 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS MERCK PATENT GmbH (DE) 2003-01-15 EP disclosed
WO-2001079186-A1 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS MERCK PATENT GMBH (DE) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224965-A1 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors NHERF1, SLC9A3, SLC9A1 MAPT 4292/4885GAA 666/4885HSP90AB1 1039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.